The Incidence and Economic Burden of Extrapyramidal Symptoms in Patients with Schizophrenia Initiating Atypical Antipsychotics in a Commercially Insured Population
Sign Up to like & getrecommendations! Published in 2022 at "CNS Spectrums"
DOI: 10.1017/s1092852922000219
Abstract: Abstract Background Extrapyramidal symptoms (EPS) affect 15% to 30% of patients with schizophrenia treated with antipsychotics and have been associated with poor patient outcomes. Objectives To examine the incidence and economic burden of EPS in… read more here.
Keywords: extrapyramidal symptoms; non eps; patients schizophrenia; economic burden ... See more keywords
The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of medical economics"
DOI: 10.1080/13696998.2021.2019501
Abstract: BACKGROUND Extrapyramidal symptoms (EPS) are common side effects of second generation antipsychotics (SGA), they can negatively impact patient quality of life, and are associated with increased morbidity and mortality. This study examined the incidence and… read more here.
Keywords: generation antipsychotics; patients schizophrenia; second generation; extrapyramidal symptoms ... See more keywords